The result is sound and aligned with guidance = $22M revenue and a loss of around $10M. Remembering that 12 Months ago we lost somewhere around $25M. This change is a huge achievement.
This years $10M loss will be reduced again in F18 hopefully to break even or better.
ADAPT sales were a little disappointing but we now have 4 products in market. 3D will be a game changer at its higher price point.
It is a real possibility immunotherapies is in the process of being divested. Hopefully some $$$ from this process.
AHZ has 12 months to prove itself IMO, after that there will be no more excuses....
Ann: Appendix 4C - quarterly, page-50
-
- There are more pages in this discussion • 111 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.25 |
Change
0.740(5.48%) |
Mkt cap ! $301.2M | |||
| Open | High | Low | Value | Volume |
| $13.60 | $14.25 | $13.35 | $309.6K | 22.39K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1150 | $14.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.25 | 314 | 1 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| AVR (ASX) Chart |